Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Возможности современной терапии первичных системных васкулитов
Возможности современной терапии первичных системных васкулитов
Зыкова А.С., Щеголева Е.М., Буланов Н.М. и др. Возможности современной терапии первичных системных васкулитов. Consilium Medicum. 2018; 20 (12): 86–93. DOI: 10.26442/20751753.2018.12.000047
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Системные васкулиты – редкая группа заболеваний, характеризующаяся неблагоприятным прогнозом без корректно подобранной терапии. Иммуносупрессивная терапия (ИСТ), представляющая собой комбинации глюкокортикостероидов и цитостатиков, а теперь и генно-инженерных биологических препаратов, повышает выживаемость при данных заболеваниях, однако может быть ассоциирована с развитием грозных осложнений. В обзоре обсуждаются основные схемы ИСТ, применяемые в лечении системных васкулитов, поражающих мелкие и крупные сосуды, текущие сложности и перспективы такого лечения.
Ключевые слова: гигантоклеточный артериит, артериит Такаясу, АНЦА-ассоциированные васкулиты, HCV-ассоциированный криоглобулинемический васкулит, клинические исследования.
Ключевые слова: гигантоклеточный артериит, артериит Такаясу, АНЦА-ассоциированные васкулиты, HCV-ассоциированный криоглобулинемический васкулит, клинические исследования.
________________________________________________
Systemic vasculitis is a group of rare diseases characterized by unfavorable prognosis without correct therapy. Today survival rate in this patient increased due to usage of modern immunosuppressive therapy (IST) which consists of combinations of glucocorticosteroids, cytostatic agents and biological drugs. Unfortunately, its use can also be associated with development of serious complications. The review discusses the basic IST regimen of vasculitis treatment their complexity and perspectives.
Key words: giant cell arteritis, Takayasu disease, ANCA associated vasculitis, HCV-associated cryoglobulinemic vasculitis, clinical studies.
Key words: giant cell arteritis, Takayasu disease, ANCA associated vasculitis, HCV-associated cryoglobulinemic vasculitis, clinical studies.
Полный текст
Список литературы
1. Jennette J. Overview of the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Clin Exp Nephrol 2013; 17 (5): 603–6. DOI: 10.1007/s10157-013-0869-6
2. Novikov P.I., Semenkova E.N., Moiseev S.V. Sovremennaia nomenklatura sistemnykh vaskulitov. Klin. farmakologiia i terapiia. 2013; 22 (1): 70–4. [in Russian]
3. Mukhin N.A., Rozina T.P, Novikov P.I. i dr. Uzelkovyi poliarteriit, assotsiirovannyi s virusom gepatita V (klinicheskii razbor). Klin. meditsina. 2015; 93 (6): 5–13. [in Russian]
4. Ignatova T.M., Chernova O.A., Burnevich E.Z., Milovanova S.Iu. Uspeshnoe lechenie HCV-krioglobulinemicheskogo vaskulita tiazhelogo techeniia s pomoshch'iu CD-20 monoklonal'nykh antitela i protivovirusnykh preparatov. Klin. meditsina. 2014; 92 (8): 62–4. [in Russian]
5. Mukhtyar C, Guillevin L, Cid M et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 68 (3): 318–23. DOI: 10.1136/ard.2008.088351
6. Mukhin N.A., Meshkov A.D., Novikov P.I. i dr. Gigantokletochnyi arteriit: klinicheskie proiavleniia i metody rannei diagnostiki. Klin. farmakologiia i terapiia. 2015; 24 (3): 79–85. [in Russian]
7. Mukhin N.A., Smitienko I.O., Novikov P.I. i dr. Takaiasu: trudnosti diagnostiki, lechenie i iskhody v kogortnom issledovanii u 128 bol'nykh. Klin. farmakologiia i terapiia. 2014; 23 (3): 55–61. [in Russian]
8. Kotter I, Henes J, Wagner A et al. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clin Exp Rheumatol 2012; 30 (1; Suppl. 70): 114–29.
9. Bienvenu B, Ly K, Lambert M et al. Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). La Revue de Médecine Interne 2016; 37 (3): 154–65. DOI: 10.1016/j.revmed.2015.12.015
10. Seror R, Baron G, Hachulla E et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis 2014; 73 (12): 2074–81. DOI: 10.1136/annrheumdis-2013-203586
11. Hoffman G, Cid M, Rendt-Zagar K et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Int Med 2007; 146 (9): 621–30.
12. Martínez-Taboada V, Rodríguez-Valverde V, Carreño L et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008; 67 (5): 625–30.
13. Loricera J, Blanco R, Hernández J et al. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients. Semin Arthr Rheum 2015; 44 (6): 717–23. DOI: 10.1016/j.semarthrit.2014.12.005
14. Régent A, Redeker S, Deroux A et al. Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients. J Rheumatol 2016; 43 (8): 1547–52. DOI: 10.3899/jrheum.151252
15. Villiger P, Adler S, Kuchen S et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2016; 387 (10031): 1921–7. DOI: 10.1016/S0140-6736(16)00560-2
16. Satybaldyev A.M., Satybaldyeva M.A., Nasonov E.L. Totsilizumab v lechenii revmaticheskoi polimialgii i gigantokletochnogo arteriita. Klin. farmakologiia i terapiia. 2017; 26 (1): 47–53. [in Russian]
17. Stone J, Tuckwell K, Dimonaco S et al. Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. Paper presented at: ACR/ARHP 2016 Annual Meeting. November 13, 2016. Available at: http://acrabstracts.org/abstract/efficacy-and-safety-of-tocilizumab-in-patients-with-giant-cell-arte.... Accessed March 27, 2017.
18. Conway R, O'Neill L, O'Flynn E et al. Ustekinumab for the treatment of refractory giant cell arteritis. Ann Rheum Dis 2016; 75 (8): 1578–9. DOI: 10.1136/annrheumdis-2016-209351
19. Hoffman G, Merkel P, Brasington R et al. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004; 50 (7): 2296–304. DOI: 10.1002/art.20300
20. Comarmond C, Plaisier E, Dahan K et al. Anti TNF-alpha in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmunity Rev 2012; 11 (9): 678–84. DOI: 10.1016/j.autrev.2011.11.025
21. Novikov P.I., Smitienko I.O., Moiseev S.V. Effektivnost' prodolzhitel'nogo lecheniia ingibitorami faktora nekroza opukholi-a pri arteriite Takaiasu, refrakternom k standartnoi immunosupressivnoi terapii. Klin. farmakologiia i terapiia. 2013; 22 (2): 44–8. [in Russian]
22. Novikov P, Smitienko I, Moiseev S. Tumor necrosis factor alpha inhibitors in patients with Takayasu's arteritis refractory to standard immunosuppressive treatment: cases series and review of the literature. Clin Rheumatol 2013; 32 (12): 1827–32. DOI: 10.1007/s10067-013-2380-6
23. Loricera J, Blanco R, Hernandez J et al. Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review. Clin Exp Rheumatol 2016; 34 (3; Suppl. 97): 44–53.
24. Park M, Lee S, Park Y, Lee S. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology 2006; 45 (5): 545–8. DOI: 10.1093/rheumatology/kei266
25. Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 2008; 58 (4): 1197–200. DOI: 10.1002/art.23373
26. Mekinian A, Comarmond C, Resche-Rigon M et al. Efficacy of Biological-Targeted Treatments in Takayasu Arteritis: Multicenter, Retrospective Study of 49 Patients. Circulation 2015; 132 (18): 1693–700. DOI: 10.1161/circulationaha.114.014321
27. Langford C, Cuthbertson D, Ytterberg S et al. A randomized, double-blind trial of abatacept (CTLA4-ig) for the treatment of Takayasu's arteritis. Arthritis Rheum 2017. DOI: 10.1002/art.40037
28. O’Connor T, Carpenter H, Bidari S et al. Role of inflammatory markers in Takayasu arteritis disease monitoring. BMC Neurology 2014; 14: 62. DOI: 10.1186/1471-2377-14-62
29. Smitienko I, Atyasova E, Moiseev S, Novikov P. MR Angiography for Evaluation of Vascular Inflammation in Patients with Takayasu's Arteritis. Paper presented at: The 18th Inernational Vasculitis and ANCA Workshop. March 25–28, 2017. Available at: http://www.anca2017.tokyo/abstracts.html. Accessed March 27, 2017.
30. Nakagomi D, Jayne D. Outcome assessment in Takayasu arteritis. Rheumatology (Oxford) 2016; 55 (7): 1159–71. DOI: 10.1093/rheumatology/kev366
31. Goglin S, Chung S. Current Treatment of Cryoglobulinemic Vasculitis. Curr Treat Options Rheumatol 2016; 2 (2): 213–24. DOI: 10.1007/s40674-016-0048-5
32. Ferri C, Greco F, Longombardo G et al. Association between hepatitis C virus and mixed cryoglobulinemia [see comment]. Clin Exp Rheumatol 1991; 9 (6): 621–4.
33. Milovanova C.Iu., Kozlovskaia L.V., Gordovskaia N.B. Polimorfizm klinicheskikh proiavlenii rioglobulinemicheskogo vaskulita, assotsiirovannogo s khronicheskim gepatitom S. Al'manakh klinicheskoi meditsiny. 2014; 30: 46–51. DOI: 10.18786/2072-0505-2014-30-46-51 [in Russian]
34. Ignatova T, Chernova O, Novikov P, Moiseev S. HCV-associated cryoglobulinaemic vasculitis: triple/dual antiviral treatment and/or rituximab? Ann Rheum Dis 2014; 73 (9): e58. DOI: 10.1136/annrheumdis-2014-205997
35. Saadoun D, Thibault V, Si Ahmed S et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis 2016; 75 (10): 1777–82. DOI: 10.1136/annrheumdis-2015-208339
36. Ferri C, Giuggioli D, Cazzato M et al. HCV-related cryoglobulinemic vasculitis: an update on its etiopathogenesis and therapeutic strategies. Clin Exp Rheum 2003; 21 (6; Suppl. 32): 78–84.
37. De Vita S, Quartuccio L, Isola M et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64 (3): 843–53. DOI: 10.1002/art.34331
38. Saadoun D, Resche Rigon M, Pol S et al. PegIFNalpha/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. J Hepatol 2015; 62 (1): 24–30. DOI: 10.1016/j.jhep.2014.08.015
39. Saadoun D, Thibault V, Si Ahmed S et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis 2016; 75 (10): 1777–82. DOI: 10.1136/annrheumdis-2015-208339
40. Bonacci M, Lens S, Londoño M et al. Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus Associated Cryoglobulinemia Treated With Direct-Acting Antivirals. Clin Gastroenterol Hepatol 2017; 15 (4): 575–83. DOI: 10.1016/j.cgh.2016.09.158
41. Saadoun D, Pol S, Ferfar Y et al. Sofosbuvir plus daclatasvir for hepatitis C virus-cryoglobulinemia vasculitis (HCV-CryoVas): VASCUVALDIC 2 Study. J Hepatol 2017; 66 (1): 56. doi.org/10.1016/S0168-8278(17)30375-6
42. Mukhtyar C, Flossmann O, Hellmich B et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008; 67 (7): 1004–10. DOI: 10.1136/ard.2007.071936
43. Flossmann O, Berden A, de Groot K et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011; 70 (3): 488–94. DOI: 10.1136/ard.2010.137778
44. Novikov P, Moiseev S, Kuznetsova E et al. Changing patterns of clinical severity and risk of mortality in granulomatosis with polyangiitis over four decades: the Russian experience. Rheumatol Int 2015; 35 (5): 891–8. DOI: 10.1007/s00296-014-3154-4
45. Hoffman G, Kerr G, Leavitt R et al. Wegener granulomatosis: an analysis of 158 patients. Ann Int Med 1992; 116 (6): 488–98. DOI: 10.7326/0003-4819-116-6-488
46. Faurschou M, Sorensen I, Mellemkjaer L et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008; 35 (1): 100–5.
47. de Groot K, Harper L, Jayne D et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150 (10): 670–80. DOI: 10.7326/0003-4819-150-10-200905190-00004
48. Harper L, Morgan M, Walsh M et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2012; 71 (6): 955–60. DOI: 10.1136/annrheumdis-2011-200477
49. Jayne D, Rasmussen N, Andrassy K et al. A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies. N Engl J Med 2003; 349 (1): 36–44. DOI: 10.1056/NEJMoa020286
50. Stone J, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363 (3): 221–32. DOI: 10.1056/NEJMoa0909905
51. Jones R, Tervaert J, Hauser T et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363 (3): 211–20. DOI: 10.1056/NEJMoa0909169
52. Yates M, Watts R, Bajema I et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016; 75 (9): 1583–94. DOI: 10.1136/annrheumdis-2016-209133
53. Novikov P.I., Zykova A.S., Smitienko I.O., Moiseev S.V. Lechenie ANTsA-assotsiirovannykh vaskulitov: rekomendatsii EULAR\ERA-EDTA 2016 goda. Klin. farmakologiia i terapiia. 2017; 26 (1): 80–7. [in Russian]
54. Guillevin L, Pagnoux C, Karras A et al. Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis. N Engl J Med 2014; 371 (19): 1771–80. DOI: 10.1056/NEJMoa1404231
55. Bekеtova T.V., Aleksandrova E.N., Novoselova T.M. i dr. Rossiiskii opyt primeneniia monoklonal'nykh antitel k V-limfotsitam (Rituksimab) pri sistemnykh vaskulitakh, assotsiirovannykh s antineitrofil'nymi tsitoplazmaticheskimi antitelami (predvaritel'nye rezul'taty rossiiskogo registra NORMA). Nauchno-prakticheskaia revmatologiia. 2014; 52 (2): 147–58. DOI: 10.14412/1995-4484-2014-147-158 [in Russian]
56. Anan'eva L.P., Solov'ev S.K., Beketova T.V. i dr. Anti-V-kletochnaia terapiia pri immunovospalitel'nykh revmaticheskikh zabolevaniiakh: effektivnost' i perenosimost' u 229 bol'nykh. Nauchno-prakticheskaia revmatologiia. 2014; 52 (5): 495–506. DOI: 10.14412/1995-4484-2014-495-506 [in Russian]
57. Novikov P, Moiseev S, Shevtsova T, Smitienko I. Short-term Efficacy and Safety of Biosimilar Rituximab in Patients with Systemic Vasculitides. Paper presented at: The 18th Inernational Vasculitis and ANCA Workshop. March 25–28, 2017. Available at: http://www.anca2017.tokyo/abstracts.html. Accessed March 27, 2017
58. Walsh M, Merkel P, Peh C et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 2013; 14: 3. DOI: 10.1186/1745-6215-14-73
59. Charles P, Terrier B, Perrodeau E et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 2018; 77 (8): 1143–9. DOI: 10.1136/annrheumdis-2017-212878
60. Lenert A, Lenert P. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Drug Design Development Ther 2015; 9: 333–47. DOI: 10.2147/DDDT.S67264
61. Mackay F, Schneider P, Rennert P, Browning J. BAFF and APRIL: a tutorial on B cell survival. Ann Rev Immunol 2003; 21: 231–64. DOI: 10.1146/annurev.immunol.21.120601.141152
62. Schiemann B, Gommerman J, Vora K et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001; 293 (5537): 2111–4. DOI: 10.1126/science.1061964
63. Bamberg C, Mackay C, Lee H et al. The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J Biol Chem 2010; 285 (10): 7633–44. DOI: 10.1074/jbc.M109.092106
64. Jayne D, Bruchfeld A, Harper L et al. MO039Successful steroid replacement in ANCA-associated vasculitis with C5A receptor inhibitor CCX168 in phase 2 randomised (CLEAR). Nephrol Dial Transplant 2016; 31 (Suppl. 1): 45. DOI: 10.1093/ndt/gfw137.01
65. Merkel PA, Niles J, Jimenez R et al. A Randomized Clinical Trial of CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with ANCA-Associated Vasculitis [abstract]. Arthritis Rheumatol 2016; 68 (Suppl. 10). Paper presented at: 2016 ACR/ARHR Annual Meeting. November 13, 2016. Available at: http://acrabstracts.org/abstract/a-randomized-clinical-trial-of-ccx168-an-orally-administered-c5ar-i.... March 27, 2017.
66. Puéchal X, Pagnoux C, Baron G et al. Prevent relapses in patients with systemic necrotizing vasulitides without poor-prognosis factors? A multicenter, double-blind randomized controlled trial. Ann Rheum Dis 2016; 75 (Suppl. 2): 77. DOI: 10.1136/annrheumdis-2016-eular.6204
67. Moiseev S, Novikov P. Five Factor Score in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss; EGPA): to use or not to use? Ann Rheum Dis 2014; 73 (3)e. 12. DOI: 10.1136/annrheumdis-2013-204809
68. Mohammad A, Hot A, Arndt F et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–Strauss). Ann Rheum Dis 2016; 75: 396–401. DOI: 10.1136/annrheumdis-2014-206095
69. Novikov P, Moiseev S, Smitienko I, Zagvozdkina E. Rituximab as induction therapy in relapsing eosinophilic granulomatosis with polyangiitis: A report of 6 cases. Joint, bone, spine 2016; 83 (1): 81–4. DOI: 10.1016/j.jbspin.2015.04.016
70. Novikov P, Moiseev S. Biologic therapy for eosinophilic granulomatosis with polyangiitis: comment on the article by Jachiet et al. Arthritis Rheumatol 2016. DOI: 10.1002/art.40015
71. Jachiet M, Samson M, Cottin V et al. Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients. Arthritis Rheumatol 2016; 68 (9): 2274–82. DOI: 10.1002/art.39663
2. Новиков П.И., Семенкова Е.Н., Моисеев С.В. Современная номенклатура системных васкулитов. Клин. фармакология и терапия. 2013; 22 (1): 70–4. / Novikov P.I., Semenkova E.N., Moiseev S.V. Sovremennaia nomenklatura sistemnykh vaskulitov. Klin. farmakologiia i terapiia. 2013; 22 (1): 70–4. [in Russian]
3. Мухин Н.А., Розина Т.П, Новиков П.И. и др. Узелковый полиартериит, ассоциированный с вирусом гепатита В (клинический разбор). Клин. медицина. 2015; 93 (6): 5–13. / Mukhin N.A., Rozina T.P, Novikov P.I. i dr. Uzelkovyi poliarteriit, assotsiirovannyi s virusom gepatita V (klinicheskii razbor). Klin. meditsina. 2015; 93 (6): 5–13. [in Russian]
4. Игнатова Т.М., Чернова О.А., Бурневич Э.З., Милованова С.Ю. Успешное лечение HCV-криоглобулинемического васкулита тяжелого течения с помощью CD-20 моноклональных антитела и противовирусных препаратов. Клин. медицина. 2014; 92 (8): 62–4. / Ignatova T.M., Chernova O.A., Burnevich E.Z., Milovanova S.Iu. Uspeshnoe lechenie HCV-krioglobulinemicheskogo vaskulita tiazhelogo techeniia s pomoshch'iu CD-20 monoklonal'nykh antitela i protivovirusnykh preparatov. Klin. meditsina. 2014; 92 (8): 62–4. [in Russian]
3. Мухин Н.А., Розина Т.П, Новиков П.И. и др. Узелковый полиартериит, ассоциированный с вирусом гепатита В (клинический разбор). Клин. медицина. 2015; 93 (6): 5–13. / Mukhin N.A., Rozina T.P, Novikov P.I. i dr. Uzelkovyi poliarteriit, assotsiirovannyi s virusom gepatita V (klinicheskii razbor). Klin. meditsina. 2015; 93 (6): 5–13. [in Russian]
5. Mukhtyar C, Guillevin L, Cid M et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 68 (3): 318–23. DOI: 10.1136/ard.2008.088351
6. Мухин Н.А., Мешков А.Д., Новиков П.И. и др. Гигантоклеточный артериит: клинические проявления и методы ранней диагностики. Клин. фармакология и терапия. 2015; 24 (3): 79–85. / Mukhin N.A., Meshkov A.D., Novikov P.I. i dr. Gigantokletochnyi arteriit: klinicheskie proiavleniia i metody rannei diagnostiki. Klin. farmakologiia i terapiia. 2015; 24 (3): 79–85. [in Russian]
7. Мухин Н.А., Смитиенко И.О., Новиков П.И. и др. Такаясу: трудности диагностики, лечение и исходы в когортном исследовании у 128 больных. Клин. фармакология и терапия. 2014; 23 (3): 55–61. / Mukhin N.A., Smitienko I.O., Novikov P.I. i dr. Takaiasu: trudnosti diagnostiki, lechenie i iskhody v kogortnom issledovanii u 128 bol'nykh. Klin. farmakologiia i terapiia. 2014; 23 (3): 55–61. [in Russian]
8. Kotter I, Henes J, Wagner A et al. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clin Exp Rheumatol 2012; 30 (1; Suppl. 70): 114–29.
9. Bienvenu B, Ly K, Lambert M et al. Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). La Revue de Médecine Interne 2016; 37 (3): 154–65. DOI: 10.1016/j.revmed.2015.12.015
10. Seror R, Baron G, Hachulla E et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis 2014; 73 (12): 2074–81. DOI: 10.1136/annrheumdis-2013-203586
11. Hoffman G, Cid M, Rendt-Zagar K et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Int Med 2007; 146 (9): 621–30.
12. Martínez-Taboada V, Rodríguez-Valverde V, Carreño L et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008; 67 (5): 625–30.
13. Loricera J, Blanco R, Hernández J et al. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients. Semin Arthr Rheum 2015; 44 (6): 717–23. DOI: 10.1016/j.semarthrit.2014.12.005
14. Régent A, Redeker S, Deroux A et al. Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients. J Rheumatol 2016; 43 (8): 1547–52. DOI: 10.3899/jrheum.151252
15. Villiger P, Adler S, Kuchen S et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2016; 387 (10031): 1921–7. DOI: 10.1016/S0140-6736(16)00560-2
16. Сатыбалдыев А.М., Сатыбалдыева М.А., Насонов Е.Л. Тоцилизумаб в лечении ревматической полимиалгии и гигантоклеточного артериита. Клин. фармакология и терапия. 2017; 26 (1): 47–53. / Satybaldyev A.M., Satybaldyeva M.A., Nasonov E.L. Totsilizumab v lechenii revmaticheskoi polimialgii i gigantokletochnogo arteriita. Klin. farmakologiia i terapiia. 2017; 26 (1): 47–53. [in Russian]
16. Сатыбалдыев А.М., Сатыбалдыева М.А., Насонов Е.Л. Тоцилизумаб в лечении ревматической полимиалгии и гигантоклеточного артериита. Клин. фармакология и терапия. 2017; 26 (1): 47–53. / Satybaldyev A.M., Satybaldyeva M.A., Nasonov E.L. Totsilizumab v lechenii revmaticheskoi polimialgii i gigantokletochnogo arteriita. Klin. farmakologiia i terapiia. 2017; 26 (1): 47–53. [in Russian]
17. Stone J, Tuckwell K, Dimonaco S et al. Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. Paper presented at: ACR/ARHP 2016 Annual Meeting. November 13, 2016. Available at: http://acrabstracts.org/abstract/efficacy-and-safety-of-tocilizumab-in-patients-with-giant-cell-arte.... Accessed March 27, 2017.
18. Conway R, O'Neill L, O'Flynn E et al. Ustekinumab for the treatment of refractory giant cell arteritis. Ann Rheum Dis 2016; 75 (8): 1578–9. DOI: 10.1136/annrheumdis-2016-209351
19. Hoffman G, Merkel P, Brasington R et al. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004; 50 (7): 2296–304. DOI: 10.1002/art.20300
20. Comarmond C, Plaisier E, Dahan K et al. Anti TNF-alpha in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmunity Rev 2012; 11 (9): 678–84. DOI: 10.1016/j.autrev.2011.11.025
21. Новиков П.И., Смитиенко И.О., Моисеев С.В. Эффективность продолжительного лечения ингибиторами фактора некроза опухоли-a при артериите Такаясу, рефрактерном к стандартной иммуносупрессивной терапии. Клин. фармакология и терапия. 2013; 22 (2): 44–8. / Novikov P.I., Smitienko I.O., Moiseev S.V. Effektivnost' prodolzhitel'nogo lecheniia ingibitorami faktora nekroza opukholi-a pri arteriite Takaiasu, refrakternom k standartnoi immunosupressivnoi terapii. Klin. farmakologiia i terapiia. 2013; 22 (2): 44–8. [in Russian]
22. Novikov P, Smitienko I, Moiseev S. Tumor necrosis factor alpha inhibitors in patients with Takayasu's arteritis refractory to standard immunosuppressive treatment: cases series and review of the literature. Clin Rheumatol 2013; 32 (12): 1827–32. DOI: 10.1007/s10067-013-2380-6
23. Loricera J, Blanco R, Hernandez J et al. Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review. Clin Exp Rheumatol 2016; 34 (3; Suppl. 97): 44–53.
24. Park M, Lee S, Park Y, Lee S. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology 2006; 45 (5): 545–8. DOI: 10.1093/rheumatology/kei266
25. Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 2008; 58 (4): 1197–200. DOI: 10.1002/art.23373
26. Mekinian A, Comarmond C, Resche-Rigon M et al. Efficacy of Biological-Targeted Treatments in Takayasu Arteritis: Multicenter, Retrospective Study of 49 Patients. Circulation 2015; 132 (18): 1693–700. DOI: 10.1161/circulationaha.114.014321
27. Langford C, Cuthbertson D, Ytterberg S et al. A randomized, double-blind trial of abatacept (CTLA4-ig) for the treatment of Takayasu's arteritis. Arthritis Rheum 2017. DOI: 10.1002/art.40037
28. O’Connor T, Carpenter H, Bidari S et al. Role of inflammatory markers in Takayasu arteritis disease monitoring. BMC Neurology 2014; 14: 62. DOI: 10.1186/1471-2377-14-62
29. Smitienko I, Atyasova E, Moiseev S, Novikov P. MR Angiography for Evaluation of Vascular Inflammation in Patients with Takayasu's Arteritis. Paper presented at: The 18th Inernational Vasculitis and ANCA Workshop. March 25–28, 2017. Available at: http://www.anca2017.tokyo/abstracts.html. Accessed March 27, 2017.
30. Nakagomi D, Jayne D. Outcome assessment in Takayasu arteritis. Rheumatology (Oxford) 2016; 55 (7): 1159–71. DOI: 10.1093/rheumatology/kev366
30. Nakagomi D, Jayne D. Outcome assessment in Takayasu arteritis. Rheumatology (Oxford) 2016; 55 (7): 1159–71. DOI: 10.1093/rheumatology/kev366
31. Goglin S, Chung S. Current Treatment of Cryoglobulinemic Vasculitis. Curr Treat Options Rheumatol 2016; 2 (2): 213–24. DOI: 10.1007/s40674-016-0048-5
32. Ferri C, Greco F, Longombardo G et al. Association between hepatitis C virus and mixed cryoglobulinemia [see comment]. Clin Exp Rheumatol 1991; 9 (6): 621–4.
33. Милованова C.Ю., Козловская Л.В., Гордовская Н.Б. Полиморфизм клинических проявлений риоглобулинемического васкулита, ассоциированного с хроническим гепатитом С. Альманах клинической медицины. 2014; 30: 46–51. DOI: 10.18786/2072-0505-2014-30-46-51 / Milovanova C.Iu., Kozlovskaia L.V., Gordovskaia N.B. Polimorfizm klinicheskikh proiavlenii rioglobulinemicheskogo vaskulita, assotsiirovannogo s khronicheskim gepatitom S. Al'manakh klinicheskoi meditsiny. 2014; 30: 46–51. DOI: 10.18786/2072-0505-2014-30-46-51 [in Russian]
34. Ignatova T, Chernova O, Novikov P, Moiseev S. HCV-associated cryoglobulinaemic vasculitis: triple/dual antiviral treatment and/or rituximab? Ann Rheum Dis 2014; 73 (9): e58. DOI: 10.1136/annrheumdis-2014-205997
35. Saadoun D, Thibault V, Si Ahmed S et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis 2016; 75 (10): 1777–82. DOI: 10.1136/annrheumdis-2015-208339
36. Ferri C, Giuggioli D, Cazzato M et al. HCV-related cryoglobulinemic vasculitis: an update on its etiopathogenesis and therapeutic strategies. Clin Exp Rheum 2003; 21 (6; Suppl. 32): 78–84.
37. De Vita S, Quartuccio L, Isola M et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64 (3): 843–53. DOI: 10.1002/art.34331
38. Saadoun D, Resche Rigon M, Pol S et al. PegIFNalpha/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. J Hepatol 2015; 62 (1): 24–30. DOI: 10.1016/j.jhep.2014.08.015
39. Saadoun D, Thibault V, Si Ahmed S et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis 2016; 75 (10): 1777–82. DOI: 10.1136/annrheumdis-2015-208339
40. Bonacci M, Lens S, Londoño M et al. Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus Associated Cryoglobulinemia Treated With Direct-Acting Antivirals. Clin Gastroenterol Hepatol 2017; 15 (4): 575–83. DOI: 10.1016/j.cgh.2016.09.158
41. Saadoun D, Pol S, Ferfar Y et al. Sofosbuvir plus daclatasvir for hepatitis C virus-cryoglobulinemia vasculitis (HCV-CryoVas): VASCUVALDIC 2 Study. J Hepatol 2017; 66 (1): 56. doi.org/10.1016/S0168-8278(17)30375-6
42. Mukhtyar C, Flossmann O, Hellmich B et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008; 67 (7): 1004–10. DOI: 10.1136/ard.2007.071936
43. Flossmann O, Berden A, de Groot K et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011; 70 (3): 488–94. DOI: 10.1136/ard.2010.137778
44. Novikov P, Moiseev S, Kuznetsova E et al. Changing patterns of clinical severity and risk of mortality in granulomatosis with polyangiitis over four decades: the Russian experience. Rheumatol Int 2015; 35 (5): 891–8. DOI: 10.1007/s00296-014-3154-4
45. Hoffman G, Kerr G, Leavitt R et al. Wegener granulomatosis: an analysis of 158 patients. Ann Int Med 1992; 116 (6): 488–98. DOI: 10.7326/0003-4819-116-6-488
46. Faurschou M, Sorensen I, Mellemkjaer L et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008; 35 (1): 100–5.
47. de Groot K, Harper L, Jayne D et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150 (10): 670–80. DOI: 10.7326/0003-4819-150-10-200905190-00004
48. Harper L, Morgan M, Walsh M et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2012; 71 (6): 955–60. DOI: 10.1136/annrheumdis-2011-200477
49. Jayne D, Rasmussen N, Andrassy K et al. A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies. N Engl J Med 2003; 349 (1): 36–44. DOI: 10.1056/NEJMoa020286
50. Stone J, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363 (3): 221–32. DOI: 10.1056/NEJMoa0909905
51. Jones R, Tervaert J, Hauser T et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363 (3): 211–20. DOI: 10.1056/NEJMoa0909169
52. Yates M, Watts R, Bajema I et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016; 75 (9): 1583–94. DOI: 10.1136/annrheumdis-2016-209133
53. Новиков П.И., Зыкова А.С., Смитиенко И.О., Моисеев С.В. Лечение АНЦА-ассоциированных васкулитов: рекомендации EULAR\ERA-EDTA 2016 года. Клин. фармакология и терапия. 2017; 26 (1): 80–7. / Novikov P.I., Zykova A.S., Smitienko I.O., Moiseev S.V. Lechenie ANTsA-assotsiirovannykh vaskulitov: rekomendatsii EULAR\ERA-EDTA 2016 goda. Klin. farmakologiia i terapiia. 2017; 26 (1): 80–7. [in Russian]
54. Guillevin L, Pagnoux C, Karras A et al. Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis. N Engl J Med 2014; 371 (19): 1771–80. DOI: 10.1056/NEJMoa1404231
55. Бекетова Т.В., Александрова Е.Н., Новоселова Т.М. и др. Российский опыт применения моноклональных антител к В-лимфоцитам (Ритуксимаб) при системных васкулитах, ассоциированных с антинейтрофильными цитоплазматическими антителами (предварительные результаты российского регистра НОРМА). Научно-практическая ревматология. 2014; 52 (2): 14758. DOI: 10.14412/1995-4484-2014-147-158 / Bekеtova T.V., Aleksandrova E.N., Novoselova T.M. i dr. Rossiiskii opyt primeneniia monoklonal'nykh antitel k V-limfotsitam (Rituksimab) pri sistemnykh vaskulitakh, assotsiirovannykh s antineitrofil'nymi tsitoplazmaticheskimi antitelami (predvaritel'nye rezul'taty rossiiskogo registra NORMA). Nauchno-prakticheskaia revmatologiia. 2014; 52 (2): 147–58. DOI: 10.14412/1995-4484-2014-147-158 [in Russian]
56. Ананьева Л.П., Соловьев С.К., Бекетова Т.В. и др. Анти-В-клеточная терапия при иммуновоспалительных ревматических заболеваниях: эффективность и переносимость у 229 больных. Научно-практическая ревматология. 2014; 52 (5): 495–506. DOI: 10.14412/1995-4484-2014-495-506 / Anan'eva L.P., Solov'ev S.K., Beketova T.V. i dr. Anti-V-kletochnaia terapiia pri immunovospalitel'nykh revmaticheskikh zabolevaniiakh: effektivnost' i perenosimost' u 229 bol'nykh. Nauchno-prakticheskaia revmatologiia. 2014; 52 (5): 495–506. DOI: 10.14412/1995-4484-2014-495-506 [in Russian]
57. Novikov P, Moiseev S, Shevtsova T, Smitienko I. Short-term Efficacy and Safety of Biosimilar Rituximab in Patients with Systemic Vasculitides. Paper presented at: The 18th Inernational Vasculitis and ANCA Workshop. March 25–28, 2017. Available at: http://www.anca2017.tokyo/abstracts.html. Accessed March 27, 2017
58. Walsh M, Merkel P, Peh C et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 2013; 14: 3. DOI: 10.1186/1745-6215-14-73
59. Charles P, Terrier B, Perrodeau E et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 2018; 77 (8): 1143–9. DOI: 10.1136/annrheumdis-2017-212878
60. Lenert A, Lenert P. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Drug Design Development Ther 2015; 9: 333–47. DOI: 10.2147/DDDT.S67264
61. Mackay F, Schneider P, Rennert P, Browning J. BAFF and APRIL: a tutorial on B cell survival. Ann Rev Immunol 2003; 21: 231–64. DOI: 10.1146/annurev.immunol.21.120601.141152
62. Schiemann B, Gommerman J, Vora K et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001; 293 (5537): 2111–4. DOI: 10.1126/science.1061964
63. Bamberg C, Mackay C, Lee H et al. The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J Biol Chem 2010; 285 (10): 7633–44. DOI: 10.1074/jbc.M109.092106
64. Jayne D, Bruchfeld A, Harper L et al. MO039Successful steroid replacement in ANCA-associated vasculitis with C5A receptor inhibitor CCX168 in phase 2 randomised (CLEAR). Nephrol Dial Transplant 2016; 31 (Suppl. 1): 45. DOI: 10.1093/ndt/gfw137.01
65. Merkel PA, Niles J, Jimenez R et al. A Randomized Clinical Trial of CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with ANCA-Associated Vasculitis [abstract]. Arthritis Rheumatol 2016; 68 (Suppl. 10). Paper presented at: 2016 ACR/ARHR Annual Meeting. November 13, 2016. Available at: http://acrabstracts.org/abstract/a-randomized-clinical-trial-of-ccx168-an-orally-administered-c5ar-i.... March 27, 2017.
66. Puéchal X, Pagnoux C, Baron G et al. Prevent relapses in patients with systemic necrotizing vasulitides without poor-prognosis factors? A multicenter, double-blind randomized controlled trial. Ann Rheum Dis 2016; 75 (Suppl. 2): 77. DOI: 10.1136/annrheumdis-2016-eular.6204
67. Moiseev S, Novikov P. Five Factor Score in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss; EGPA): to use or not to use? Ann Rheum Dis 2014; 73 (3)e. 12. DOI: 10.1136/annrheumdis-2013-204809
68. Mohammad A, Hot A, Arndt F et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–Strauss). Ann Rheum Dis 2016; 75: 396–401. DOI: 10.1136/annrheumdis-2014-206095
69. Novikov P, Moiseev S, Smitienko I, Zagvozdkina E. Rituximab as induction therapy in relapsing eosinophilic granulomatosis with polyangiitis: A report of 6 cases. Joint, bone, spine 2016; 83 (1): 81–4. DOI: 10.1016/j.jbspin.2015.04.016
70. Novikov P, Moiseev S. Biologic therapy for eosinophilic granulomatosis with polyangiitis: comment on the article by Jachiet et al. Arthritis Rheumatol 2016. DOI: 10.1002/art.40015
71. Jachiet M, Samson M, Cottin V et al. Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients. Arthritis Rheumatol 2016; 68 (9): 2274–82. DOI: 10.1002/art.39663
________________________________________________
2. Novikov P.I., Semenkova E.N., Moiseev S.V. Sovremennaia nomenklatura sistemnykh vaskulitov. Klin. farmakologiia i terapiia. 2013; 22 (1): 70–4. [in Russian]
3. Mukhin N.A., Rozina T.P, Novikov P.I. i dr. Uzelkovyi poliarteriit, assotsiirovannyi s virusom gepatita V (klinicheskii razbor). Klin. meditsina. 2015; 93 (6): 5–13. [in Russian]
4. Ignatova T.M., Chernova O.A., Burnevich E.Z., Milovanova S.Iu. Uspeshnoe lechenie HCV-krioglobulinemicheskogo vaskulita tiazhelogo techeniia s pomoshch'iu CD-20 monoklonal'nykh antitela i protivovirusnykh preparatov. Klin. meditsina. 2014; 92 (8): 62–4. [in Russian]
5. Mukhtyar C, Guillevin L, Cid M et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 68 (3): 318–23. DOI: 10.1136/ard.2008.088351
6. Mukhin N.A., Meshkov A.D., Novikov P.I. i dr. Gigantokletochnyi arteriit: klinicheskie proiavleniia i metody rannei diagnostiki. Klin. farmakologiia i terapiia. 2015; 24 (3): 79–85. [in Russian]
7. Mukhin N.A., Smitienko I.O., Novikov P.I. i dr. Takaiasu: trudnosti diagnostiki, lechenie i iskhody v kogortnom issledovanii u 128 bol'nykh. Klin. farmakologiia i terapiia. 2014; 23 (3): 55–61. [in Russian]
8. Kotter I, Henes J, Wagner A et al. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clin Exp Rheumatol 2012; 30 (1; Suppl. 70): 114–29.
9. Bienvenu B, Ly K, Lambert M et al. Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). La Revue de Médecine Interne 2016; 37 (3): 154–65. DOI: 10.1016/j.revmed.2015.12.015
10. Seror R, Baron G, Hachulla E et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis 2014; 73 (12): 2074–81. DOI: 10.1136/annrheumdis-2013-203586
11. Hoffman G, Cid M, Rendt-Zagar K et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Int Med 2007; 146 (9): 621–30.
12. Martínez-Taboada V, Rodríguez-Valverde V, Carreño L et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008; 67 (5): 625–30.
13. Loricera J, Blanco R, Hernández J et al. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients. Semin Arthr Rheum 2015; 44 (6): 717–23. DOI: 10.1016/j.semarthrit.2014.12.005
14. Régent A, Redeker S, Deroux A et al. Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients. J Rheumatol 2016; 43 (8): 1547–52. DOI: 10.3899/jrheum.151252
15. Villiger P, Adler S, Kuchen S et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2016; 387 (10031): 1921–7. DOI: 10.1016/S0140-6736(16)00560-2
16. Satybaldyev A.M., Satybaldyeva M.A., Nasonov E.L. Totsilizumab v lechenii revmaticheskoi polimialgii i gigantokletochnogo arteriita. Klin. farmakologiia i terapiia. 2017; 26 (1): 47–53. [in Russian]
17. Stone J, Tuckwell K, Dimonaco S et al. Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. Paper presented at: ACR/ARHP 2016 Annual Meeting. November 13, 2016. Available at: http://acrabstracts.org/abstract/efficacy-and-safety-of-tocilizumab-in-patients-with-giant-cell-arte.... Accessed March 27, 2017.
18. Conway R, O'Neill L, O'Flynn E et al. Ustekinumab for the treatment of refractory giant cell arteritis. Ann Rheum Dis 2016; 75 (8): 1578–9. DOI: 10.1136/annrheumdis-2016-209351
19. Hoffman G, Merkel P, Brasington R et al. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004; 50 (7): 2296–304. DOI: 10.1002/art.20300
20. Comarmond C, Plaisier E, Dahan K et al. Anti TNF-alpha in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmunity Rev 2012; 11 (9): 678–84. DOI: 10.1016/j.autrev.2011.11.025
21. Novikov P.I., Smitienko I.O., Moiseev S.V. Effektivnost' prodolzhitel'nogo lecheniia ingibitorami faktora nekroza opukholi-a pri arteriite Takaiasu, refrakternom k standartnoi immunosupressivnoi terapii. Klin. farmakologiia i terapiia. 2013; 22 (2): 44–8. [in Russian]
22. Novikov P, Smitienko I, Moiseev S. Tumor necrosis factor alpha inhibitors in patients with Takayasu's arteritis refractory to standard immunosuppressive treatment: cases series and review of the literature. Clin Rheumatol 2013; 32 (12): 1827–32. DOI: 10.1007/s10067-013-2380-6
23. Loricera J, Blanco R, Hernandez J et al. Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review. Clin Exp Rheumatol 2016; 34 (3; Suppl. 97): 44–53.
24. Park M, Lee S, Park Y, Lee S. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology 2006; 45 (5): 545–8. DOI: 10.1093/rheumatology/kei266
25. Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 2008; 58 (4): 1197–200. DOI: 10.1002/art.23373
26. Mekinian A, Comarmond C, Resche-Rigon M et al. Efficacy of Biological-Targeted Treatments in Takayasu Arteritis: Multicenter, Retrospective Study of 49 Patients. Circulation 2015; 132 (18): 1693–700. DOI: 10.1161/circulationaha.114.014321
27. Langford C, Cuthbertson D, Ytterberg S et al. A randomized, double-blind trial of abatacept (CTLA4-ig) for the treatment of Takayasu's arteritis. Arthritis Rheum 2017. DOI: 10.1002/art.40037
28. O’Connor T, Carpenter H, Bidari S et al. Role of inflammatory markers in Takayasu arteritis disease monitoring. BMC Neurology 2014; 14: 62. DOI: 10.1186/1471-2377-14-62
29. Smitienko I, Atyasova E, Moiseev S, Novikov P. MR Angiography for Evaluation of Vascular Inflammation in Patients with Takayasu's Arteritis. Paper presented at: The 18th Inernational Vasculitis and ANCA Workshop. March 25–28, 2017. Available at: http://www.anca2017.tokyo/abstracts.html. Accessed March 27, 2017.
30. Nakagomi D, Jayne D. Outcome assessment in Takayasu arteritis. Rheumatology (Oxford) 2016; 55 (7): 1159–71. DOI: 10.1093/rheumatology/kev366
31. Goglin S, Chung S. Current Treatment of Cryoglobulinemic Vasculitis. Curr Treat Options Rheumatol 2016; 2 (2): 213–24. DOI: 10.1007/s40674-016-0048-5
32. Ferri C, Greco F, Longombardo G et al. Association between hepatitis C virus and mixed cryoglobulinemia [see comment]. Clin Exp Rheumatol 1991; 9 (6): 621–4.
33. Milovanova C.Iu., Kozlovskaia L.V., Gordovskaia N.B. Polimorfizm klinicheskikh proiavlenii rioglobulinemicheskogo vaskulita, assotsiirovannogo s khronicheskim gepatitom S. Al'manakh klinicheskoi meditsiny. 2014; 30: 46–51. DOI: 10.18786/2072-0505-2014-30-46-51 [in Russian]
34. Ignatova T, Chernova O, Novikov P, Moiseev S. HCV-associated cryoglobulinaemic vasculitis: triple/dual antiviral treatment and/or rituximab? Ann Rheum Dis 2014; 73 (9): e58. DOI: 10.1136/annrheumdis-2014-205997
35. Saadoun D, Thibault V, Si Ahmed S et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis 2016; 75 (10): 1777–82. DOI: 10.1136/annrheumdis-2015-208339
36. Ferri C, Giuggioli D, Cazzato M et al. HCV-related cryoglobulinemic vasculitis: an update on its etiopathogenesis and therapeutic strategies. Clin Exp Rheum 2003; 21 (6; Suppl. 32): 78–84.
37. De Vita S, Quartuccio L, Isola M et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64 (3): 843–53. DOI: 10.1002/art.34331
38. Saadoun D, Resche Rigon M, Pol S et al. PegIFNalpha/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. J Hepatol 2015; 62 (1): 24–30. DOI: 10.1016/j.jhep.2014.08.015
39. Saadoun D, Thibault V, Si Ahmed S et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis 2016; 75 (10): 1777–82. DOI: 10.1136/annrheumdis-2015-208339
40. Bonacci M, Lens S, Londoño M et al. Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus Associated Cryoglobulinemia Treated With Direct-Acting Antivirals. Clin Gastroenterol Hepatol 2017; 15 (4): 575–83. DOI: 10.1016/j.cgh.2016.09.158
41. Saadoun D, Pol S, Ferfar Y et al. Sofosbuvir plus daclatasvir for hepatitis C virus-cryoglobulinemia vasculitis (HCV-CryoVas): VASCUVALDIC 2 Study. J Hepatol 2017; 66 (1): 56. doi.org/10.1016/S0168-8278(17)30375-6
42. Mukhtyar C, Flossmann O, Hellmich B et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008; 67 (7): 1004–10. DOI: 10.1136/ard.2007.071936
43. Flossmann O, Berden A, de Groot K et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011; 70 (3): 488–94. DOI: 10.1136/ard.2010.137778
44. Novikov P, Moiseev S, Kuznetsova E et al. Changing patterns of clinical severity and risk of mortality in granulomatosis with polyangiitis over four decades: the Russian experience. Rheumatol Int 2015; 35 (5): 891–8. DOI: 10.1007/s00296-014-3154-4
45. Hoffman G, Kerr G, Leavitt R et al. Wegener granulomatosis: an analysis of 158 patients. Ann Int Med 1992; 116 (6): 488–98. DOI: 10.7326/0003-4819-116-6-488
46. Faurschou M, Sorensen I, Mellemkjaer L et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008; 35 (1): 100–5.
47. de Groot K, Harper L, Jayne D et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150 (10): 670–80. DOI: 10.7326/0003-4819-150-10-200905190-00004
48. Harper L, Morgan M, Walsh M et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2012; 71 (6): 955–60. DOI: 10.1136/annrheumdis-2011-200477
49. Jayne D, Rasmussen N, Andrassy K et al. A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies. N Engl J Med 2003; 349 (1): 36–44. DOI: 10.1056/NEJMoa020286
50. Stone J, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363 (3): 221–32. DOI: 10.1056/NEJMoa0909905
51. Jones R, Tervaert J, Hauser T et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363 (3): 211–20. DOI: 10.1056/NEJMoa0909169
52. Yates M, Watts R, Bajema I et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016; 75 (9): 1583–94. DOI: 10.1136/annrheumdis-2016-209133
53. Novikov P.I., Zykova A.S., Smitienko I.O., Moiseev S.V. Lechenie ANTsA-assotsiirovannykh vaskulitov: rekomendatsii EULAR\ERA-EDTA 2016 goda. Klin. farmakologiia i terapiia. 2017; 26 (1): 80–7. [in Russian]
54. Guillevin L, Pagnoux C, Karras A et al. Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis. N Engl J Med 2014; 371 (19): 1771–80. DOI: 10.1056/NEJMoa1404231
55. Bekеtova T.V., Aleksandrova E.N., Novoselova T.M. i dr. Rossiiskii opyt primeneniia monoklonal'nykh antitel k V-limfotsitam (Rituksimab) pri sistemnykh vaskulitakh, assotsiirovannykh s antineitrofil'nymi tsitoplazmaticheskimi antitelami (predvaritel'nye rezul'taty rossiiskogo registra NORMA). Nauchno-prakticheskaia revmatologiia. 2014; 52 (2): 147–58. DOI: 10.14412/1995-4484-2014-147-158 [in Russian]
56. Anan'eva L.P., Solov'ev S.K., Beketova T.V. i dr. Anti-V-kletochnaia terapiia pri immunovospalitel'nykh revmaticheskikh zabolevaniiakh: effektivnost' i perenosimost' u 229 bol'nykh. Nauchno-prakticheskaia revmatologiia. 2014; 52 (5): 495–506. DOI: 10.14412/1995-4484-2014-495-506 [in Russian]
57. Novikov P, Moiseev S, Shevtsova T, Smitienko I. Short-term Efficacy and Safety of Biosimilar Rituximab in Patients with Systemic Vasculitides. Paper presented at: The 18th Inernational Vasculitis and ANCA Workshop. March 25–28, 2017. Available at: http://www.anca2017.tokyo/abstracts.html. Accessed March 27, 2017
58. Walsh M, Merkel P, Peh C et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 2013; 14: 3. DOI: 10.1186/1745-6215-14-73
59. Charles P, Terrier B, Perrodeau E et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 2018; 77 (8): 1143–9. DOI: 10.1136/annrheumdis-2017-212878
60. Lenert A, Lenert P. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Drug Design Development Ther 2015; 9: 333–47. DOI: 10.2147/DDDT.S67264
61. Mackay F, Schneider P, Rennert P, Browning J. BAFF and APRIL: a tutorial on B cell survival. Ann Rev Immunol 2003; 21: 231–64. DOI: 10.1146/annurev.immunol.21.120601.141152
62. Schiemann B, Gommerman J, Vora K et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001; 293 (5537): 2111–4. DOI: 10.1126/science.1061964
63. Bamberg C, Mackay C, Lee H et al. The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J Biol Chem 2010; 285 (10): 7633–44. DOI: 10.1074/jbc.M109.092106
64. Jayne D, Bruchfeld A, Harper L et al. MO039Successful steroid replacement in ANCA-associated vasculitis with C5A receptor inhibitor CCX168 in phase 2 randomised (CLEAR). Nephrol Dial Transplant 2016; 31 (Suppl. 1): 45. DOI: 10.1093/ndt/gfw137.01
65. Merkel PA, Niles J, Jimenez R et al. A Randomized Clinical Trial of CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with ANCA-Associated Vasculitis [abstract]. Arthritis Rheumatol 2016; 68 (Suppl. 10). Paper presented at: 2016 ACR/ARHR Annual Meeting. November 13, 2016. Available at: http://acrabstracts.org/abstract/a-randomized-clinical-trial-of-ccx168-an-orally-administered-c5ar-i.... March 27, 2017.
66. Puéchal X, Pagnoux C, Baron G et al. Prevent relapses in patients with systemic necrotizing vasulitides without poor-prognosis factors? A multicenter, double-blind randomized controlled trial. Ann Rheum Dis 2016; 75 (Suppl. 2): 77. DOI: 10.1136/annrheumdis-2016-eular.6204
67. Moiseev S, Novikov P. Five Factor Score in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss; EGPA): to use or not to use? Ann Rheum Dis 2014; 73 (3)e. 12. DOI: 10.1136/annrheumdis-2013-204809
68. Mohammad A, Hot A, Arndt F et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–Strauss). Ann Rheum Dis 2016; 75: 396–401. DOI: 10.1136/annrheumdis-2014-206095
69. Novikov P, Moiseev S, Smitienko I, Zagvozdkina E. Rituximab as induction therapy in relapsing eosinophilic granulomatosis with polyangiitis: A report of 6 cases. Joint, bone, spine 2016; 83 (1): 81–4. DOI: 10.1016/j.jbspin.2015.04.016
70. Novikov P, Moiseev S. Biologic therapy for eosinophilic granulomatosis with polyangiitis: comment on the article by Jachiet et al. Arthritis Rheumatol 2016. DOI: 10.1002/art.40015
71. Jachiet M, Samson M, Cottin V et al. Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients. Arthritis Rheumatol 2016; 68 (9): 2274–82. DOI: 10.1002/art.39663
Авторы
А.С.Зыкова*1, Е.М.Щеголева2, Н.М.Буланов2, П.И.Новиков2, С.В.Моисеев1,2
1 ФГБОУ ВО «Московский государственный университет им. М.В.Ломоносова». 119192, Россия, Москва, Ломоносовский пр., д. 31, корп. 5;
2 ФГАОУ ВО «Первый Московский государственный университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
1 ФГБОУ ВО «Московский государственный университет им. М.В.Ломоносова». 119192, Россия, Москва, Ломоносовский пр., д. 31, корп. 5;
________________________________________________
A.S.Zykova*1, E.M.Schegoleva2, N.M.Bulanov2, P.I.Novikov2, S.V.Moiseev1,2
1 M.V.Lomonosov Moscow State University. 119192, Russian Federation, Moscow, Lomonosovskii pr., d. 31, korp. 5;
2 I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 21 M.V.Lomonosov Moscow State University. 119192, Russian Federation, Moscow, Lomonosovskii pr., d. 31, korp. 5;
*ansezy@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.